Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David Frazier Jarrard, Yu-Hui Chen, Glenn Liu, Michael Anthony Carducci, Mario A. Eisenberger, Yu-Ning Wong, Noah M. Hahn, Manish Kohli, Matthew M. Cooney, Robert Dreicer, Nicholas J. Vogelzang, Joel Picus, Daniel H. Shevrin, Maha Hussain, Jorge A. Garcia, Robert S. DiPaola, Christopher Sweeney
Institutions: University of Wisconsin–Madison, UW Health University Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University of Wisconsin Carbone Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Fox Chase Cancer Center, Mayo Clinic, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, University of Virginia, Comprehensive Cancer Centers of Nevada, Washington University in St. Louis, Endeavor Health, University of Michigan, Cleveland Clinic, University of Kentucky
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2597597364